Spectrum of ASXL1 mutations in primary myelofibrosis: prognostic impact of the ASXL1 p.G646Wfs*12 mutation

Blood. 2019 Jun 27;133(26):2802-2808. doi: 10.1182/blood.2018879536. Epub 2019 May 10.

Giada Rotunno^{1

2}, Carmela Mannarelli^{1

2}, Giada Brogi^{1

2}, Annalisa Pacilli^{1

2}, Francesca Gesullo^{1

2}, Francesco Mannelli^{1

2}, Sara Fiaccabrino^{1

2}, Benedetta Sordi^{1

2}, Chiara Paoli^{1

2}, Ilaria Marone^{1

2}, Elisa Rumi³, Rossella Manfredini⁴, Giovanni Barosi⁵, Mario Cazzola³, Alessandro M Vannucchi^{1

2}, Paola Guglielmelli^{1

2}

¹ Centro di Ricerca e Innovazione per le Malattie Mieloproliferative (CRIMM), Dipartimento di Medicina Sperimentale e Clinica, Azienda Ospedaliera Universitaria Careggi, and.
² Excellence Centre for Research, Transfer and High Education for the Development of DE NOVO Therapies (DENOTHE), Università degli Studi Firenze, Florence, Italy.
³ Department of Hematology Oncology, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Policlinico San Matteo, University of Pavia, Pavia, Italy.
⁴ Center for Regenerative Medicine Stefano Ferrari, University of Modena and Reggio Emilia, Modena, Italy; and.
⁵ Center for the Study of Myelofibrosis, IRCCS Policlinico S. Matteo Foundation, Pavia, Italy.

No abstract available

Publication types